ProstaLund
A stable quarter with growth and new agreements
MAR
1 July-30 September
- Net sales reached SEK 3,8 (3,7) million
- Loss after taxes SEK -2,1 (-1,7) million
- Earnings per share were SEK -0,04 SEK (-0,03)
- Cash and equivalents were 15,9 (16,7) million
Significant events during period
- The company carried out a rights issue which brought the company approximately SEK 19.8 million in capital before issue costs
- A letter of intent regarding the distribution agreement for China is signed
- Agreement with Capio Specialistmottagning, Lund
- Distribution agreement signed for Brazil
1 January-30 September
- Net sales reached SEK 11,9 (12,1) million
- Loss after taxes SEK -8,0 (-5,7) million
- Earnings per share were SEK -0,15 SEK (-0,12)
Significant events after the end of the period
- Results for the registry study on prostate cancer are presented at the Urologidagarna in Malmö by one of the authors
- Distribution agreement signed for Spain
Key figures | ||||
(SEK MILLION) | Jan-Sep 2022 | Jan-Sep 2021 | Jan-Sep 2020 | Jan-Sep 2019 |
Net sales | 11,9 | 12,1 | 8,8 | 9,5 |
Gross margin, % | 77 | 85 | 71 | 67 |
Operating profit/loss | -7,7 | -5,6 | -6,2 | -8,1 |
Cash flow from operating activities | -13,0 | -6,3 | -6,2 | -6,6 |
Average number of employees | 7 | 7 | 5 | 5 |
“There is no longer any doubt that we have world-class products”
Johan Wennerholm
CEO, ProstaLund AB (publ)
Please see attached PDF for full report.
Datum | 2022-10-21, kl 08:15 |
Källa | MFN |

Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet